Mayim Bialik Says Her GLP-1 Experience Was a 'Nightmare'
Mayim Bialik tried a GLP-1 medication on the advice of her doctor. She describes what followed as a nightmare.
The "Big Bang Theory" star and former "Jeopardy!" host, 50, published a personal essay in The Free Press on June 5 detailing her experience with the widely used class of weight-loss and metabolic drugs. She was prescribed the medication not for weight loss but because a doctor suggested it might help manage symptoms from Graves' disease, an autoimmune condition affecting the thyroid that she was diagnosed with at 23.
"I was exhausted from being sick, from the endless parade of specialists, from the diets, the protocols, and the promises," Bialik wrote. "Maybe this could be the magic cure."
It was not.
What She Experienced
Bialik wrote that she was advised to take one shot of the lowest available dose of a synthetic GLP-1. The side effects were severe and immediate.
She described "explosive, uncontrollable diarrhea," sulfur burps so intense she was afraid to open her mouth in public, and sneezing attacks every time she tried to eat or drink — a phenomenon she noted has an actual medical name: snatiation. She also experienced cramping, bloating, full-body aching, and an inability to keep down even small sips of water.
"To say I had an adverse reaction would be somewhat of an understatement," she wrote.
The symptoms left her, in her own words, too sick to stand, drink water, or think clearly. She noted that more than three times, she did not make it to the bathroom in time.
What Her Doctor Said
Bialik visited a gastroenterologist seeking answers. According to her essay, the doctor told her that her dramatic symptoms were not unusual and that GLP-1 medications are extremely disruptive to the body. He advised that they should not be taken lightly.
The experience gave her what she described as a new and deeper empathy for people living with Crohn's disease, irritable bowel syndrome, colitis, and other chronic gastrointestinal conditions.
Bialik's Broader Health History
Bialik has been managing multiple overlapping health conditions for years. In addition to Graves' disease, she has been diagnosed with connective tissue disease, mast cell activation syndrome, and Sjögren's syndrome. She wrote that she had been prescribed medication for Graves' disease early on but did not make the dietary and lifestyle changes that were also recommended — something she believes may have gradually worsened her condition over time.
She entered the GLP-1 conversation already familiar with the medications through social media advertising, influencer endorsements, and the proliferation of online services offering compounded versions of the drugs.
The Bigger Picture on GLP-1 Side Effects
Bialik's experience sits on the more severe end of the spectrum, but it is not medically unusual. Gastrointestinal issues are among the most commonly reported side effects of GLP-1 medications, including nausea, vomiting, diarrhea, constipation, bloating, and in some cases gastroparesis — a condition sometimes called stomach paralysis.
A large study published in 2025 became one of the first comprehensive efforts to catalog the full range of GLP-1 risks and benefits. It confirmed that the drugs are associated with a lower risk of heart attack, stroke, and other cardiovascular problems, and that people taking them had fewer seizures and lower rates of addiction to alcohol, cannabis, and opioids. On the other side, the study also found associations with several negative health outcomes, with gastrointestinal complications topping the list.
More serious but less common risks include acute pancreatitis, gallbladder disease, and in rare cases vision problems. Several major manufacturers including Novo Nordisk and Eli Lilly are currently facing thousands of lawsuits from patients who allege the drugs' makers failed to adequately warn of certain severe injury risks.
For many patients, GLP-1 medications have been genuinely life-changing in a positive direction. For others, the side effects make them unworkable. Bialik's account is a reminder that the conversation around these drugs — still often dominated by before-and-after success stories — has another side worth hearing.
Curious for more stories that keep you informed and entertained? From the latest headlines to everyday insights, YourLifeBuzz has more to explore. Dive into what’s next.